Related Experiment Videos
[Cryptogenetic ulcerative colitis. Our clinical experience with new therapeutic approaches]
O Cigala1, M T Pancallo, A Marasco
1Clinica delle Malattie Tropicali ed infettive, Università degli Studi di Roma La Sapienza.
La Clinica Terapeutica
|July 31, 1990
Summary
Oral 5-aminosalicylic acid (5-ASA) effectively treated ulcerative colitis flare-ups in 16 patients. Most patients experienced symptom remission with good or very good results after 30 days of treatment.
Area of Science:
- Gastroenterology
- Internal Medicine
- Pharmacology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Flare-ups significantly impact patient quality of life.
- Effective and well-tolerated treatments are needed for UC management.
Purpose of the Study:
- To evaluate the efficacy and tolerability of oral 5-aminosalicylic acid (5-ASA) in patients experiencing ulcerative colitis flare-ups.
Main Methods:
- Sixteen patients with active ulcerative colitis were enrolled.
- Treatment involved oral administration of 2-4 g of 5-ASA daily for 30 days.
- Patients underwent laboratory tests, contrast enema X-rays, and endoscopic examinations with biopsies before and after treatment.
Main Results:
- One patient (6.25%) discontinued 5-ASA due to intolerance.
- The remaining 15 patients (93.75%) achieved good or very good clinical results.
- Symptom remission was observed in the majority of patients treated with 5-ASA.
Conclusions:
- Oral 5-ASA demonstrates high efficacy and good tolerability for managing ulcerative colitis flare-ups.
- 5-ASA is a valuable therapeutic option for inducing remission in UC patients.
- The study supports the use of 5-ASA in clinical practice for ulcerative colitis management.